Phase II study of PCNU in the treatment of head and neck carcinoma.
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D004341:Drug Evaluation; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011379:Prognosis
D009607:Nitrosourea Compounds; C018627:1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea